Saturday, July 11, 2026

Drug profile · INN

piflufolastat (18f)

piflufolastat (18f) (PYLCLARI) is a diagnostic agent.

EMA: approved Various (V09) V09
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — piflufolastat (18f)
Class
Various (V09)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

piflufolastat (18f) (PYLCLARI) is a diagnostic agent.

Key facts

INN piflufolastat (18f)
Brand PYLCLARI
Mechanism Diagnostic agent
Therapeutic class Various (V09)
ATC code V09

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. CAAA617D12302 Phase 3 · Novartis India · Oligometastatic prostate cancer (OMPC)
  2. CAMO959A12103 Phase 2 · Novartis India · PSMA-positive mCRPC with prior exposure to at least one prio

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. sugammadex sodium Various (V03)

Frequently asked questions

What is piflufolastat (18f)?

piflufolastat (18f) (PYLCLARI) is a diagnostic agent.

What is the brand name for piflufolastat (18f)?

PYLCLARI is a marketed brand name for piflufolastat (18f). Check FDA Drugs@FDA for the current US label holder and prescribing information.